Navigation Links
BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB

ProductsBEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB
Company BioFit Engineered Products
Item BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB
Features Inquire
Description Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top performance in a variety of environments including: industry, education, laboratory, clean room, static control, health care and office. • With cast aluminum base
Info BioFit Engineered Products
Customer Service: (800) 597-0246

Related medicine products :

1. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q70-ERB
2. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q51-R-ERB
3. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q70-R-ERB
4. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q52-R-ERB
5. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-R-ERB
6. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q43-ERB
7. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q53-R-ERB
8. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q73-ERB
9. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q64-ERB
10. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q43-R-ERB
11. BEC/1Q-ERB - Cast Aluminum Base - Model 1Q64-R-ERB
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 1Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 2Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 3Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 4Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 5Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 6Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 7Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 8Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 9Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 10Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 11Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 12Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 13Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 14Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 15Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 16Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 17Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics 3rd Edition The Report 14262 18The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 1The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston MA Hynes Convention Center October 31 November 3 20 5061 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 1American Society of Plastic Surgeons hosts 78th annual meeting 58275 2American Society of Plastic Surgeons hosts 78th annual meeting 58275 3